Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Stryjewski, ME, and Corey, GR. "Methicillin-resistant Staphylococcus aureus: an evolving pathogen." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 58 Suppl 1 (January 2014): S10-S19. (Review)

PMID
24343827
Full Text

Tsalik, EL, Langley, RJ, Dinwiddie, DL, Miller, NA, Yoo, B, van Velkinburgh, JC, Smith, LD, Thiffault, I, Jaehne, AK, Valente, AM, Henao, R, Yuan, X, Glickman, SW, Rice, BJ, McClain, MT, Carin, L, Corey, GR, Ginsburg, GS, Cairns, CB, Otero, RM, Fowler, VG, Rivers, EP, Woods, CW, and Kingsmore, SF. "An integrated transcriptome and expressed variant analysis of sepsis survival and death." Genome medicine 6, no. 11 (January 2014): 111-.

PMID
25538794
Full Text

Corey, GR, Kollef, MH, Shorr, AF, Rubinstein, E, Stryjewski, ME, Hopkins, A, and Barriere, SL. "Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival." Antimicrob Agents Chemother 58, no. 4 (2014): 2030-2037.

PMID
24419353
Full Text

Stryjewski, ME, Lentnek, A, O'Riordan, W, Pullman, J, Tambyah, PA, Miró, JM, Jr, VGF, Barriere, SL, Kitt, MM, and Corey, GR. "A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: The ASSURE study." BMC Infectious Diseases 14, no. 1 (2014).

Full Text

Corey, GR, Kollef, MH, Shorr, AF, Rubinstein, E, Stryjewski, ME, Hopkins, A, and Barriere, SL. "Erratum: Telavancin for hospital-Acquired pneumonia: Clinical response and 28-day survival (Antimicrobial Agents and Chemotherapy (2014) 58:4 (2030-2037))." Antimicrobial Agents and Chemotherapy 58, no. 6 (January 1, 2014): 3581-.

Full Text

Moran, GJ, Fang, E, Corey, GR, Das, AF, De Anda, C, and Prokocimer, P. "Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial." The Lancet Infectious Diseases 14, no. 8 (January 1, 2014): 696-705.

Full Text

Corey, GR, Jiang, H, and Moeck, G. "Dr. Corey and colleagues reply." New England Journal of Medicine 371, no. 12 (January 1, 2014): 1162-1163. (Letter)

Full Text

Carugati, M, Bayer, AS, Miró, JM, Park, LP, Guimarães, AC, Skoutelis, A, Fortes, CQ, Durante-Mangoni, E, Hannan, MM, Nacinovich, F, Fernández-Hidalgo, N, Grossi, P, Tan, RS, Holland, T, Fowler, VG, Corey, RG, and Chu, VH. "High-dose daptomycin therapy for left-sided infective endocarditis: A prospective study from the international collaboration on endocarditis." Antimicrobial Agents and Chemotherapy 57, no. 12 (December 1, 2013): 6213-6222.

PMID
24080644
Full Text

Lalani, T, Chu, VH, Park, LP, Cecchi, E, Corey, GR, Durante-Mangoni, E, Jr, FVG, Gordon, D, Grossi, P, Hannan, M, Hoen, B, Munoz, P, Rizk, H, Kanj, SS, Selton-Suty, C, Sexton, DJ, Spelman, D, Ravasio, V, Tripodi, MF, Wang, A, and Endocarditis-Pro, IC. "In-Hospital and 1-Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis." JAMA INTERNAL MEDICINE 173, no. 16 (September 9, 2013): 1495-1504.

PMID
23857547
Full Text

Catania, J, Martin, SS, Corey, GR, and Sexton, DS. "Diagnostic dilemma in a returning traveler with fever." Diagnostic microbiology and infectious disease 77, no. 1 (September 2013): 85-86.

PMID
23871414
Full Text

Pages